International Journal of Medical Sciences · 2018 · 25 citations · 25 references
MedicinePharmacologyApoptosisBiochemical PharmacologyBone MetabolismBone FormationBone HealingOsteoblast BiologyOsteoclast BiologyOsteoclast FunctionOsteogenesisAntioxidant PropertiesOsteoblast Differentiation In CalvariaOsteoprotegerin RegulationPropofol UseRankl Opg PathwayRankl Opg SignalingRankl-mediated OsteoclastogenesisRankl-opg Signaling Axis
Bone remodeling plays an important role in the bone healing process; for example, following fracture. The relative ratio of the receptor activator of nuclear factor kappa B ligand (RANKL)/ osteoprotegerin (OPG) controls osteoclast differentiation, thereby playing a pivotal role in the regulation of bone remodeling. Propofol, a widely used anesthetic agent in orthopedic procedures, is considered to possess potential antioxidant properties owing to its structural similarity to α-tocopherol. Antioxidants are known to enhance bone healing. Accordingly, in the present study, we aimed to investigate osteoblastic differentiation and RANKL/OPG expression following propofol administration, in order to assess the potentially beneficial effects of this drug on the bone remodeling process, using calvarial primary osteoblasts from newborn mice. Calvarial pre-osteoblast cells were cultured in media containing clinically relevant concentrations of propofol, and cytotoxicity, effects on cell proliferation, osteogenic activity, and osteoclastogenesis were examined. The present findings indicated that propofol did not exert cytotoxic effects or alter cell proliferation in primary calvarial osteoblasts. Further, propofol did not affect osteoblast differentiation. The RANKL/OPG ratio was found to be decreased following propofol administration, and osteoclastogenesis was significantly reduced, indicating that propofol attenuated the osteoclastogenesis-supporting activity of osteoblasts. The results demonstrate that propofol, at clinically relevant concentrations, exerts beneficial effects on bone remodeling by attenuating osteoclastogenesis via suppression of the RANKL/OPG expression axis.
25
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.5K citations · Full text
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
W. Scott Simonet, Dave Lacey, Colin R. Dunstan et al. · Cell · 1997 · 5.1K citations · Full text
Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.3K citations
Novel Regulators of Bone Formation: Molecular Clones and Activities
John M. Wozney, Vicki Rosen, Anthony Celeste et al. · Science · 1988 · 3.9K citations
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Tomoki Nakashima, Mikihito Hayashi, Takanobu Fukunaga et al. · Nature Medicine · 2011 · 1.7K citations
Medicine, Cell Biology, Physiology +16